Renal Cancer
IL-1A is associated with postoperative survival and immune contexture in clear cell renal cell carcinoma.
January 21, 2022
A Bioinformatic Analysis of Immune-Related Prognostic Genes in Clear Cell Renal Cell Carcinoma Based on TCGA and GEO Databases.
January 20, 2022
Risk of recurrence after nephrectomy: Comparison of predictive ability of validated risk models.
January 19, 2022
Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.
January 19, 2022
Risk-group Classification by Recursive Partitioning Analysis of Patients Affected by Oligometastatic Renal Cancer Treated with Stereotactic Radiotherapy.
January 18, 2022
Surgical outcomes for older patients with renal cell carcinoma and inferior vena cava thrombus.
January 18, 2022
Prognostic Significance of NLR About NETosis and Lymphocytes Perturbations in Localized Renal Cell Carcinoma With Tumor Thrombus.
January 14, 2022
cMET - a prognostic marker in papillary renal cell carcinoma?
January 13, 2022
Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma.
January 13, 2022
A 17-Gene Expression Signature for Early Identification of Poor Prognosis in Clear Cell Renal Cell Carcinoma.
January 13, 2022
The renal clear cell carcinoma immune landscape.
January 12, 2022
Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.
January 11, 2022